The invention provides a non-naturally occurring bacterium having decreased or eliminated activity of an enzyme that catalyzes the reaction defined by EC 1.2.7.5, such as aldehyde:ferredoxin oxidoreductase (AOR). Optionally, the bacterium also has decreased or eliminated activity of an enzyme that catalyzes the reaction defined by EC 1.2.1.10 and/or EC 1.1.1.1, such as aldehyde dehydrogenase, alcohol dehydrogenase, or bifunctional aldehyde/alcohol dehydrogenase. The invention further provides methods of producing products by culturing the bacterium in the presence of a gaseous substrate containing one or more of CO, CO.sub.2, and H.sub.2.

A composition includes two exogenous enzymes from animals for consumption by human beings to prevent, treat and/or alleviate veisalgia and/or symptoms associated therewith arising from or caused by consumption or spontaneous production of alcohol through a dual-enzyme based breakdown of the alcohol, wherein a first enzyme of the two exogenous enzymes is capable of converting alcohol into a first metabolite while a second enzyme thereof is capable of converting the first metabolite into a second metabolite which is excretable to systemic circulation after an oxidation reaction of the alcohol in the presence of the two exogenous enzymes and NAD.sup.+/NADH, and wherein the first enzyme to the second enzyme is in a molar ratio of 1:3-51 in the composition in order to avoid an elevation in the level of the first metabolite in the human being.

Described herein are plasmid addiction systems comprising a host cell comprising one or more inactivated host cell essential genes; and a plasmid comprising one or more plasmid essential genes operably linked to a constitutively active promoter. Also described herein are metabolism-based plasmid addiction systems (PAS) comprising a host cell and a plasmid operably linked to a constitutively active promoter for producing value-based products (e.g., 1-butanol) and methods of generating PASs in microorganisms and producing 1-butanol from a PAS in the absence of antibiotics and/or co-inducers.

Methods for increasing the genetic stability of genetically enhanced microbial host cells capable of producing a compound of interest are disclosed.

The present invention provides a pharmaceutical composition containing 10 mg to about 100 g KRED and/or a long-acting alcohol dehydrogenase as an active ingredient and a pharmaceutically acceptable carrier. Moreover, provided herein methods for lowering blood alcohol level, methods for preventing a symptom or a risk arising from alcohol consumption and methods for treating a subject afflicted with alcoholism by the administration of the pharmaceutical composition of the invention.

Disclosed is a method of producing lactic acid using a recombinant acid-resistant yeast with inhibited lactate metabolism and alcohol production. More specifically, disclosed are a recombinant acid-resistant yeast in which lactate consumption reaction is reduced and which is imparted with lactic-acid-producing ability to thereby exhibit improved lactic-acid-producing ability and reduced ethanol production, and a method of producing lactic acid using the same.

The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metabolic pathway on or off. When turned on, the recombinant bacterial cells complete all of the steps in a metabolic pathway to achieve a therapeutic effect in a host subject. These recombinant bacterial cells are designed to drive therapeutic effects throughout the body of a host from a point of origin of the microbiome. Specifically, the present disclosure provides recombinant bacterial cells comprising a heterologous gene encoding a branched chain amino acid catabolism enzyme. The disclosure further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders involving the catabolism of branched chain amino acids using the pharmaceutical compositions disclosed herein.

The present invention relates to recombinant bacteria and the uses thereof, particularly for the production of ethanol. The invention also relates to methods for the production of such bacteria, as well as to nucleic acid constructs suitable for such production. The invention specifically relates to bacteria lacking a functional LDH gene and/or containing a recombinant nucleic acid encoding a PDC and ADH. The bacteria of this invention may be produced from any stress-resistant bacteria.

The invention relates to ketoreductases and the use thereof. The ketoreductases of the invention are particularly useful for enzymatically catalyzing the reduction of ketones to chiral secondary alcohols.

An ethanologen for producing biofuel from one or more carbohydrates and reducing lactate and acetate production in a biofuel manufacturing process. The ethanologen is made by introducing into the ethanologen one or more exogenous genes required for production of a bacteriocin. The resulting ethanologen reduces lactate and acetate production by contaminant lactic acid bacteria by expression of the bacteriocin during the biofuel manufacturing process. Certain resulting ethanologens ferment sugars not naturally or not preferentially utilized by Saccharomyces cerevisiae during the manufacturing process.